Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside chat on November 16. Cardiff's lead drug, onvansertib, is in Phase 2 trials targeting RAS-mutated metastatic colorectal cancer, addressing a significant unmet medical need. Investors can access the live webcast and replay through Cardiff's website.
Cardiff Oncology's participation in the UBS Global Biopharma Conference provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: out of 150 priced US health-sector stocks, 74 rose and 69 fell. Notable movers include AHCO (AdaptHealth Corp) at USD 6.20 with a 4.91% increase and a typical hold time of 21 days, NUVB (Nuvation Bio Inc.) at USD 4.81 up 4.79%, and ACB (Aurora Cannabis Inc) at USD 4.40 up 4.27%.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
The global potato chips market is expected to grow from $59.67 billion in 2026 to $84.26 billion by 2032, at a CAGR of 5.88%. Growth is fueled by local manufacturing, individual packaging, and flavor innovation, which help brands meet diverse consume...
